Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Clin Immunol. 2005 Nov;1(4):495-510. doi: 10.1586/1744666X.1.4.495.

Levocetirizine: a modern H1-antihistamine for the treatment of allergic rhinitis.

Author information

1
Department of Oto-Rhino-Laryngology, Univerisity Hospital, De Pintelaan 185, 9000 Ghent, Belgium. claus.bachert@ugent.be

Abstract

Levocetirizine is the latest of the H(1)-antihistamines indicated for adults and children (as young as 2 years old) suffering from allergic rhinitis and chronic idiopathic urticaria. Currently, it is the only therapy registered for treatment of persistent allergic rhinitis, as defined by the Allergic Rhinitis & its Impact on Asthma guidelines. Pharmacologic studies have shown levocetirizine to have a more favorable pharmacokinetic/pharmacodynamic profile than other commonly employed H(1)-antihistamines. This reflects its superiority in controlling the symptoms of seasonal, perennial and persistent allergic rhinitis in well-controlled trials. Clinical trials and postmarketing surveillance have indicated that levocetirizine is safe and well tolerated, and leads to clinically significant improvements in the quality of life of patients. It is also reported to reduce comorbidities as well as overall treatment costs when administered continuously over the longterm.

PMID:
20477594
DOI:
10.1586/1744666X.1.4.495
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center